Balancing bleeding in brain metastases

Slides:

Advertisements

Similar presentations

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Advertisements

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

Alternate designs for conduct and analysis of phase I cancer trials

VEGF therapy: risky business for established plaques?

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Defects in DBA: more than meets the eye

Slit-Robo Cancer Cell Volume 4, Issue 1, Pages 1-2 (July 2003)

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Tax fingerprint in adult T-cell leukemia

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Mechanical Properties of Stored Red Blood Cells Using Optical Tweezers

Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,

Solid cancers after allogeneic hematopoietic cell transplantation

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

Fusion genes in cord blood

Genetic sequence analysis of inherited bleeding diseases

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

How we choose factor VIII to treat hemophilia

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience by Régis Peffault.

An actuarial GPS for hemophilic longevity

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Anergy: the CLL cell limbo

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Sabina Kersting, Leo F. Verdonck

Emerging Strategies for Treating Brain Metastases from Breast Cancer

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

How I treat cancer-associated venous thromboembolism

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Björn Redfors et al. JACEP 2017;j.jacep

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

by Wendy Lim, Sara K. Vesely, and James N. George

79-Year-Old Man With Fever, Malaise, and Jaundice

Treatment versus Transplant for Challenging Hematologic Disorders

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Dana V. Rizk, David G. Warnock Kidney International

Sickle cells and sickle trait in thrombosis

BRCA1 and BRCA2 Testing: Weighing the Demand against the Benefits

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Trends in the use of head CT and advanced imaging in patients treated with IV thrombolysis from 2008 to Trends in the use of head CT and advanced.

Bar graph of ADC values (s/mm2) for tumor, contralateral normal tissue, ipsilateral normal tissue, and edema for the group of 15 patients with high-grade.

Rituximab immunotherapy: it’s getting personal

A binding relationship with thrombin

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Typical images of a patient without brain metastases derived via automatic segmentation software. Typical images of a patient without brain metastases.

Change in FES uptake in the tumor during fulvestrant treatment.

Cold agglutinin disease

Presentation transcript:

Balancing bleeding in brain metastases by Lisa Baumann Kreuziger Blood Volume 126(4):432-433 July 23, 2015 ©2015 by American Society of Hematology

Cumulative incidence of ICH in patients with metastatic brain tumors. Cumulative incidence of ICH in patients with metastatic brain tumors. No difference in (A) the cumulative incidence of total and (B) significant ICH (>10 mL, symptomatic, or necessitating neurosurgery) was found in cancer patients with brain metastases when the control group (blue) was compared with patients treated with enoxaparin (red). See Figure 1B-C in the article by Donato et al that begins on page 494. Lisa Baumann Kreuziger Blood 2015;126:432-433 ©2015 by American Society of Hematology